£10,000 invested in Diageo shares before Ozempic is now worth…
The invention of Ozempic has been a disaster for the Diageo (LSE: DGE) share price. The weight loss drug, also known by its generic name semaglutide or sold as Wegovy, has the peculiar side effect of causing users to drink less. Reasons given include worse hangovers and not getting the same âbuzzâ.Â
As a Diageo shareholder, Iâm watching the situation with the Guinness, Smirnoff, and Tanqueray manufacturer with interest. With 27% of British adults being obese and 64% being overweight or obese, use of these anti-obesity treatments might become more and more widespread.Â
Does that mean we are inching inexorably toward a future overflowing with skinny teetotallers and with a cratered Diageo share price? Or have the rumours of the demise of alcohol been greatly exaggerated? Letâs explore.
Problems
While Ozempic and its counterparts burst onto the scene in 2017, the drugs only gained widespread adoption a few years after. The Diageo share price maps more or less neatly onto their proliferation. Let’s examine the pre-Ozempic high of Diageo shares to see how bad the fall is.
The shares reached an all-time high of £40.36 on New Yearâs Eve of 2021, a time when weight loss drugs were still the preserve of dodgy ads on shady websites. The shares slowly fell to £18.93 on the day that I write this, a staggering fall of 53%.Â
While other issues have plagued the alcohol beverage multinational, notably falling consumption by Gen Z and supply chain issues in Latin America, a £10,000 stake bought at the top would have fallen to £4,690 today. To add insult to injury, the FTSE 100 has been soaring over the same time period. A £10,000 stake in a Footsie index fund would have swelled to £12,634. I excluded dividends from these calculations, by the way.
Holding on
If thereâs a lesson to be learned here, itâs that sometimes you have to chalk it up to the game. In other words, these things happen in investing. Things come out of the blue and make a once very attractive stock look quite a bit less attractive.
Could I have predicted the decline in alcohol consumption among the latest batch of young adults? Probably not. And Iâm not in the habit of making investment decisions based on the invention of revolutionary new drugs either. I bought Diageo because it looked like a great stock.
On fundamentals, it still looks like a great stock in many respects. Guinness is one of the most popular beers going. And its zero alcohol version is similarly loved among the no-drinking and âsober curiousâ crowds. A forward price-to-earnings ratio of just 14 looks very reasonable too. Itâs for these reasons that I plan to hold onto my shares in spite of my despair at the worsening outlook.
The post £10,000 invested in Diageo shares before Ozempic is now worth… appeared first on The Motley Fool UK.
Should you invest £1,000 in Diageo plc right now?
When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.
And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Diageo plc made the list?
More reading
- Why Diageo shares fell 14% in September
- Down another 15% in September! Is Diageo now the best share to buy or the very worst?
- Are UK shares entering the danger zone?
- These 3 high-yield dividend shares could benefit from falling UK interest rates
- When will the Diageo share price stop diving?
John Fieldsend has positions in Diageo Plc. The Motley Fool UK has recommended Diageo Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.
